Publication date: Jul 23, 2026
The recurrent outbreaks and geographical expansion of mosquito-borne arboviruses pose a significant challenge to public health worldwide. The disease outcome for arboviral infections ranges from acute febrile illness to severe conditions such as encephalitis, hemorrhagic shock, and mortality. Current treatment options for these viruses are limited to supportive care, necessitating an urgent need for a safe and effective broad-spectrum antiviral. In this study, we have identified trifluoperazine (TFP), an FDA-approved antipsychotic, as a potent broad-spectrum antiviral against Japanese encephalitis virus (JEV), Dengue virus (DENV), and Chikungunya virus (CHIKV) infections. The antiviral effect of TFP was also seen in the animal models of JEV and CHIKV with significantly reduced disease severity. Mechanistically, TFP treatment increased the phosphorylation of eIF2a and induced an adaptive ER stress response in diverse cell types. Alleviation of TFP-induced ER stress by chemical chaperone 4PBA abolished the antiviral activity of the drug and rescued virus replication in cells and CHIKV mice model. The robust in vitro and in vivo efficacy of the drug against arboviruses highlights the potential for repurposing TFP as a broad-spectrum antiviral candidate and underscores the importance of ER stress as a therapeutic target.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Alleviation | Arboviruses |
| Arboviruses | broad-spectrum antiviral |
| Fda | Chikungunya virus |
| Japanese | Dengue virus |
| Trifluoperazine | ER stress |
| Japanese encephalitis virus | |
| trifluoperazine |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Trifluoperazine |
| disease | MESH | infections |
| disease | MESH | encephalitis |
| disease | MESH | hemorrhagic shock |
| disease | MESH | Japanese encephalitis |
| disease | MESH | Dengue |